Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
  • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/35—Ketones, e.g. benzophenone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/37—Esters of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
  • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/52—Stabilizers
  • A61K2800/522—Antioxidants; Radical scavengers

Definitions

• the present invention relates generally to methods of treating skin.
• the present invention concerns topical skin care compositions that include ingredients found to have beneficial effect on skin.
• ingredients can have rather unpleasant odors.
• Such ingredients include nitrogen-containing compounds, heterocyclic compounds, and sulfur-containing compounds. The end result is the production of cosmetic compositions that have foul odors.
• Odor neutralizing ingredients have been used to reduce or mask malodorous cosmetic compositions.
• aromatic chemical compounds and blends of such compounds has been successful in this regard. Examples of such ingredients can be found in the International Cosmetic Ingredient Dictionary and Handbook, 10 th Edition (2004).
• one of the problems associated with using malodorous skin-active ingredients is that additional chemical ingredients may have to be used to mask the unpleasant odors caused by the skin-active ingredient.
• the inventors have discovered new uses of aromatic chemical compounds that have previously been thought to be useful only as odor neutralizing agents.
• the inventors have identified certain aromatic chemical compounds that are cosmeceutically effective in treating skin or skin cells or preventing skin or skin cell damage while also being capable of reducing, masking, or preventing the intensity of malodorous smelling cosmetic compositions (e.g., aromatic skin-active ingredients or compounds). Therefore the compositions of the present invention can exclude or reduce the amount of odor neutralizing compounds in instances where an aromatic skin-active ingredient of the present invention is used.
• the inventors contemplate the use of odor neutralizing compounds in compositions that also include the aromatic skin-active ingredients disclosed throughout this specification.
• a method of treating or preventing a skin condition comprising topically applying a composition that includes an aromatic skin-active ingredient on skin, wherein the topical application of the composition treats or prevents the skin condition.
• a cosmeceutically effective amount of the aromatic skin-active ingredient is applied on the skin.
• Non-limiting examples of a cosmeceutically effective amount include 0.005% to 2.0% by weight of the composition (note that other ranges are contemplated and disclosed throughout this specification).
• the aromatic skin-active ingredient can be selected from the group consisting of those identified in Table 1 below (e.g., 1,4-dioxacycloheptadecane-5,17-dione; (3E)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)but-3-en-2-one; 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethan-1-one; 1-(2,3,8,8-tetramethyl-1,2,3,5,6,7,8,8a-octahydronaphthalen-2-yl)ethanone; 1-(2,3,8,8-tetramethyl-1,2,3,4,6,7,8,8a-octahydronaphthalen-2-yl)ethanone; 4-methyl-3-decen-5-ol; 2,6-dimethyl-5-heptenal; 3,3-dimethyl-5(2,2,3-trimethyl-3
• the composition can include a single aromatic skin-active ingredient or any combination of aromatic skin active ingredients.
• the composition can include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the aromatic skin-active ingredients, including any combination thereof.
• Non-limiting examples of skin conditions include pruritus, spider veins, lentigo, age spots, senile purpura, keratosis, melasma, blotches, fine lines or wrinkles, nodules, sun damaged skin, dermatitis (including, but not limited to seborrheic dermatitis, nummular dermatitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, perioral dermatitis, and stasis dermatitis), psoriasis, folliculitis, rosacea, acne, impetigo, erysipelas, erythrasma, eczema, and other inflammatory skin conditions.
• dermatitis including, but not limited to seborrheic dermatitis, nummular dermatitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, perioral dermatitis, and stas
• the skin condition can be caused by exposure to UV light, age, irradiation, chronic sun exposure, environmental pollutants, air pollution, wind, cold, heat, chemicals, disease pathologies, smoking, or lack of nutrition.
• the skin can be facial skin or non-facial skin (e.g., arms, legs, hands, chest, back, feet, etc.).
• the method can further comprise identifying a person in need of skin treatment.
• the person can be a male or female.
• the age of the person can be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or more years old, or any range derivable therein.
• the method can include topically applying an amount effective to: increase the stratum corneum turnover rate of the skin; increase collagen synthesis in fibroblasts; increase cellular anti-oxidant defense mechanisms (e.g., exogenous additions of anti-oxidants can bolster, replenish, or prevent the loss of cellular antioxidants such as catalase and glutathione in skin cells (e.g., keratinocytes, melanocytes, langerhans cells, etc.); inhibit melanin production in melanocytes; reduce or prevent oxidative damage to skin (including reducing the amount lipid peroxides and/or protein oxidation in the skin).
• cellular anti-oxidant defense mechanisms e.g., exogenous additions of anti-oxidants can bolster, replenish, or prevent the loss of cellular antioxidants such as catalase and glutathione in skin cells (e.g., keratinocytes, melanocytes, langerhans cells, etc.); inhibit melanin production in melanocytes; reduce or prevent
• a method of reducing or preventing lipoxygenase, cyclooxygenase (COX), tumor necrosis factor-alpha (TNF- ⁇ ), or matrix metalloproteinase (MMP) enzyme activity in a cell comprising contacting the cell with an aromatic skin-active ingredient, wherein contacting the cell with the aromatic ingredient reduces or prevents lipoxygenase, cyclooxygenase (COX), tumor necrosis factor-alpha (TNF- ⁇ ), or matrix metalloproteinase (MMP) enzyme activity in the cell.
• COX cyclooxygenase
• TNF- ⁇ tumor necrosis factor-alpha
• MMP matrix metalloproteinase
• a method of reducing or preventing oxidative damage in a cell comprising contacting the cell with an aromatic skin-active ingredient, wherein contacting the cell with the aromatic ingredient reduces oxidative damage in the cell.
• the cell can be a skin cell.
• skin cells include human epidermal keratinocytes, human dermal fibroblasts, or human melanocytes.
• Non-limiting examples of cyclooxygenase include cyclooxygenase-1 or cyclooxygenase-2.
• Non-limiting examples of matrix metalloproteinase enzyme include MMP3 or MMP9.
• the aromatic skin-active ingredient can be selected from the group consisting of those identified in Table I below.
• the aromatic skin-active ingredient is comprised in a composition.
• the cells can be contacted with a single aromatic skin-active ingredient or any combination of aromatic skin active ingredients.
• the cells can be contacted with at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the aromatic skin-active ingredients, including any combination thereof.
• compositions of the present invention can decrease the amount of internal oxidation and/or external oxidative damage in a cell.
• the compositions can increase collagen synthesis in a cell.
• the compositions can also reduce skin inflammation, such as by reducing inflammatory cytokine production in a cell.
• Non-limiting examples of such cells include human epidermal keratinocyte, human fibroblast dermal cell, human melanocytes, three dimensional human cell-derived in vitro tissue equivalents comprising human keratinocytes, human fibroblasts, or human melanocytes, or any combination thereof (e.g., combination of human keratinocytes and human fibroblasts or a combination of human keratinocytes and human melanocytes).
• a method of lightening skin or evening skin tone comprising applying the compositions of the present invention to the skin.
• the method can further comprise identify a person in need of lightening skin or evening skin tone.
• the methods can further include inhibiting melanogenesis in a skin cell, inhibiting tyrosinase or tyrosinase synthesis in a skin cell, or inhibiting melanin transport to keratinocytes in a skin cell.
• the composition can act as an alpha melanin stimulatory hormone antagonist.
• the composition can even out pigmentation of the skin.
• lightening skin can include reducing the appearance of an age spot, a skin discoloration, or a freckle.
• a method of treating hyperpigmentation comprising applying the compositions of the present invention to the skin.
• the method can also comprise identifying a person in need of treating hyperpigmentation. Additional methods contemplated by the inventor include methods for reducing the appearance of an age spot, a skin discoloration, or a freckle, reducing or preventing the appearance of fine lines or wrinkles in skin, or increasing the firmness of skin.
• compositions comprising an effective amount of an aromatic skin-active ingredient or combination of such ingredients.
• the composition can be a topical skin-care composition.
• the aromatic skin-active ingredient can be selected from the group consisting of: those identified in Table 1 below.
• the composition can be fragrance free.
• the composition does not include another aromatic compound.
• the composition does not include another skin-active ingredient in certain embodiments and/or does not include another aromatic compound.
• the composition can include a single aromatic skin-active ingredient or any combination of aromatic skin active ingredients.
• the composition can include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the aromatic skin-active ingredients, including any combination thereof.
• compositions can work together synergistically or in a complementary fashion to produce effects that exceed the effects of what would be expected if the extracts were used in separate compositions.
• Non-limiting synergistic effects include the reduction of internal or external oxidative damage, increased collagen production, reduction in inflammatory responses and the inhibition of melanogenesis, or reduce or prevent lipoxygenase, cyclooxygenase (COX), tumor necrosis factor-alpha (TNF- ⁇ ), or matrix metalloproteinase (MMP) enzyme activity in a skin cell.
• the compositions are formulated into topical skin care compositions.
• the compositions can be cosmetic compositions.
• compositions can be formulated as emulsions (e.g., oil-in-water and water-in-oil emulsions), creams, lotions, solutions (e.g., aqueous or hydro-alcoholic solutions), anhydrous bases (e.g., lipstick or a powder), gels, and ointments.
• emulsions e.g., oil-in-water and water-in-oil emulsions
• creams e.g., lotions, solutions (e.g., aqueous or hydro-alcoholic solutions), anhydrous bases (e.g., lipstick or a powder), gels, and ointments.
• the compositions of the present invention can be included in anti-aging, cleansing, or moisturizing products.
• the compositions can also be formulated for topical skin application at least 1, 2, 3, 4, 5, 6, 7, or more times a day during use.
• compositions can be storage stable or color stable, or both.
• the viscosity of the composition can be selected to achieve a desired result (e.g., depending on the type of composition desired, the viscosity of such composition can be from about 1 cps to well over 1 million cps or any range or integer derivable therein (e.g., 2 cps, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1000000 cps, etc.
• a desired result e.g., depending on the type of composition desired, the viscosity of such composition can be from about 1 cps to well over 1 million cps
• compositions of the present invention can also be modified to have a desired oxygen radical absorbance capacity (ORAC) value.
• ORAC oxygen radical absorbance capacity
• the compositions of the present invention can be modified to have an ORAC value per mg of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 15000, 20000, 30000, 50000, 100000 or more or any range derivable therein.
• compositions in non-limiting aspects can have a pH of about 6 to about 9.
• the pH can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14.
• the compositions can be sunscreens having a sun protection factor (SPF) of 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or more.
• SPDF sun protection factor
• the compositions include odor neutralizing ingredients other than the aromatic skin-active ingredients disclosed throughout this specification.
• kits that includes the compositions of the present invention.
• the composition is comprised in a container.
• the container can be a bottle, dispenser, or package.
• the container can dispense a pre-determined amount of the composition.
• the compositions is dispensed in a spray, dollop, or liquid.
• the container can include indicia on its surface. The indicia can be a word, an abbreviation, a picture, or a symbol.
• a product comprising a composition of the present invention.
• the product can be a cosmetic product.
• the cosmetic product can be those described in other sections of this specification or those known to a person of skill in the art.
• Non-limiting examples of products include a moisturizer, a cream, a lotion, a skin softener, a foundation, a night cream, a lipstick, a cleanser, a toner, a sunscreen, a mask, or an anti-aging product.
• an “effective,” as that term is used in the specification and/or claims, means adequate to accomplish a desired, expected, or intended result.
• an “effective amount” or a “cosmeceutically effective amount” or a “therapeutically effective amount” means an amount that is adequate to accomplish a desired, expected, or intended result.
• an aromatic skin-active ingredient(s) in the methods and compositions of the present invention can include an “effective amount” or a “cosmeceutically effective amount” or a “therapeutically effective amount.” Such amounts can vary depending on the aromatic skin-active ingredient(s), the condition to be treated or prevented and its severity, the manner of administration, and the age of the person to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
• the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
• the inventors have discovered new uses of aromatic chemical compounds that have previously been thought to be useful only as odor neutralizing agents. As explained in non-limiting aspects in the following sections, the aromatic skin-active ingredients discovered by the inventors have been shown to be effective at treating a wide range of skin ailments and preventing skin damage. These compounds can be incorporated into all types of cosmetic compositions. These and other aspect of the present invention are described in further non-limiting detail below.
• the inventor has discovered that the compounds listed in Table 1 have surprising and unexpected properties that are beneficial to human skin. Data supporting these properties (including how these data were obtained) are presented in the EXAMPLES section below which is incorporated into this section by reference.
• the beneficial properties of these compounds range from reducing or preventing oxidative damage to skin or skin cells, reducing or preventing lipoxygenase activity in skin or skin cells, reducing or inhibiting cyclooxygenase (COX) activity in skin or skin cells, reducing or inhibiting tumor necrosis factor alpha (TNF- ⁇ ) in skin or skin cells, and reducing or inhibiting matrix metalloproteinase (MMP) enzyme activity in skin or skin cells.
• COX cyclooxygenase
• TNF- ⁇ tumor necrosis factor alpha
• MMP matrix metalloproteinase
• aromatic skin-active compounds and derivatives and modifications of the same can be prepared by using convention chemical synthesis techniques (see, e.g., Organic Chemistry, 5 th Ed., which is incorporated by reference).
• Free radicals are chemically active molecular fragments that have a charge due to excess or a deficient number of electrons.
• Reactive oxygen species ROS
• free radicals containing oxygen ROS
• ROS reactive oxygen species
• oxidative damage In aged skin, oxidative damage accumulates which results in lost skin elasticity and increased fine lines and wrinkles.
• Antioxidants block the oxidation process by neutralizing, or reduce, this energy to protect cellular functions and prevent damage to cell proteins. Thus, reductions in oxidative damage in skin can reduce the signs of signs of premature aging.
• Lipoxygenase enzymes catalyze the oxidative conversion of arachadonic acid to hydroxyeicosotrienenoic (HETE), that are subsequently converted to leukotrienes. Increased levels of arachadonic acid is associated with sustained inflammation in human skin. Thus, compounds which reduce the activity of lipoxygenase enzymes can act as a potent mediator of skin inflammation.
• HETE hydroxyeicosotrienenoic
• COX is a bifunctional enzyme exhibiting both cyclooxygenase and peroxidase activities.
• the cyclooxygenase activity converts arachadonic acid to a hydroperoxy endoperoxide (Prostaglandin G2; PGG2) and the peroxidase component reduces the endoperoxide (Prostaglandin H2; PGH2) to the precursor of prostaglandins, thromboxanes, and prostacyclins, key mediators of skin inflammation.
• PGG2 hydroperoxy endoperoxide
• PGH2 peroxidase
• compounds which reduce the enzymatic activity of COX will also mediate the inflammatory response in skin.
• TNF- ⁇ Tumor Necrosis Factor-Alpha
• MMPs are extracellular proteases whose substrates include the extracellular matrix proteins which comprise the skin dermal compartment.
• MMP3 substrates include collagens, fibronectins, and laminin
• MMP9 substrates include collagen VII, fibronectin, and laminin.
• the these enzymes work to destroy the proteins which provide support for the skin. Therefore, reduction in the activity of these enzymes inhibits the destruction of these proteins.
• compounds which inhibit the activity of MMPs will result increased amounts of collagen and other dermal matrix proteins.
• Non-limiting examples of modifications that can be made to such ingredients include the addition or removal of lower alkyls such as methyl, ethyl, propyl, or substituted lower alkyls such as hydroxymethyl or aminomethyl groups; carboxyl groups and carbonyl groups; hydroxyls; nitro, amino, amide, and azo groups; sulfate, sulfonate, sulfono, sulfhydryl, sulfonyl, sulfoxido, phosphate, phosphono, phosphoryl groups, and halide substituents.
• lower alkyls such as methyl, ethyl, propyl, or substituted lower alkyls such as hydroxymethyl or aminomethyl groups
• carboxyl groups and carbonyl groups hydroxyls; nitro, amino, amide, and azo groups
• the compositions can include in their final form, for example, at least about 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012%, 0.0013%, 0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%, 0.0022%, 0.0023%, 0.0024%, 0.0025%, 0.0026%, 0.0027%, 0.0028%, 0.0029%, 0.0030%, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%, 0.0038%, 0.0039%, 0.0040%, 0.0041%, 0.0042%, 0.0043%, 0.0044%, 0.0045%, 0.0046%, 0.0047%, 0.0048%,
• aromatic skin-active ingredients and additional ingredients identified throughout this specification can be encapsulated for delivery to a target area such as skin.
• encapsulation techniques include the use of liposomes, vesicles, and/or nanoparticles (e.g., biodegradable and non-biodegradable colloidal particles comprising polymeric materials in which the ingredient is trapped, encapsulated, and/or absorbed-examples include nanospheres and nanocapsules) that can be used as delivery vehicles to deliver such ingredients to skin (see, e.g., U.S. Pat. No. 6,387,398; U.S. Pat. No. 6,203,802; U.S. Pat. No. 5,411,744; Kreuter 1998).
• compositions that do not produce an allergic or similar untoward reaction when administered to a human.
• compositions are prepared either as topical compositions, liquid solutions or suspensions, solid forms suitable for solution in, or suspension in, liquid prior to use can also be prepared.
• Routes of administration can vary with the location and nature of the condition to be treated, and include, e.g., topical, inhalation, intradermal, transdermal, parenteral, intravenous, intramuscular, intranasal, subcutaneous, percutaneous, intratracheal, intraperitoneal, intratumoral, perfusion, lavage, direct injection, and oral administration and formulation.
• compositions of the present invention can include additional ingredients.
• additional ingredients include cosmetic ingredients (both active and non-active) and pharmaceutical ingredients (both active and non-active).
• fragrances artificial and natural
• dyes and color ingredients e.g., Blue 1, Blue 1 Lake, Red 40, titanium dioxide, D&C blue no. 4, D&C green no. 5, D&C orange no. 4, D&C red no. 17, D&C red no. 33, D&C violet no. 2, D&C yellow no. 10, and D&C yellow no.
• Non-limiting examples of pharmaceutical ingredients include anti-acne agents, agents used to treat rosacea, analgesics, anesthetics, anorectals, antihistamines, anti-inflammatory agents including non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antimicrobials, anti-cancer actives, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatic agents, antiseborrheic agents, biologically active proteins and peptides, burn treatment agents, cauterizing agents, depigmenting agents, depilatories, diaper rash treatment agents, enzymes, hair growth stimulants, hair growth retardants including DFMO and its salts and analogs, hemostatics, kerotolytics, canker sore treatment agents, cold sore treatment agents, dental and periodontal treatment agents, photosensitizing actives, skin
• Kits are also contemplated as being used in certain aspects of the present invention.
• a composition of the present invention can be included in a kit.
• a kit can include a container.
• Containers can include a bottle, a metal tube, a laminate tube, a plastic tube, a dispenser, a pressurized container, a barrier container, a package, a compartment, a lipstick container, a compact container, cosmetic pans that can hold cosmetic compositions, or other types of containers such as injection or blow-molded plastic containers into which the dispersions or compositions or desired bottles, dispensers, or packages are retained.
• the kit and/or container can include indicia on its surface.
• the indicia for example, can be a word, a phrase, an abbreviation, a picture, or a symbol.
• the containers can dispense a pre-determined amount of a composition.
• the container can be squeezed (e.g., metal, laminate, or plastic tube) to dispense a desired amount of the composition.
• the composition can be dispensed as a spray, an aerosol, a liquid, a fluid, or a semi-solid.
• the containers can have spray, pump, or squeeze mechanisms.
• a kit can also include instructions for using the kit and/or compositions. Instructions can include an explanation of how to apply, use, and maintain the compositions.
• Neofolione ⁇ 27.46% ⁇ 53.90%
• Precyclemone B ⁇ 25.09% Cyclacet ⁇ 26.37% Melanol ⁇ 20.45% Floralozone ⁇ 33.20% Calone 1951 ⁇ 21.26%
• the antioxidant system of living organisms includes enzymes such as superoxide dismutase, catalase, and glutathione peroxidase; macromolecules such as albumin, ceruloplasmin, and ferritin; and an array of small molecules, including ascorbic acid, ⁇ -tocopherol, ⁇ -carotene, reduced glutathione, uric acid, and bilirubin.
• enzymes such as superoxide dismutase, catalase, and glutathione peroxidase
• macromolecules such as albumin, ceruloplasmin, and ferritin
• small molecules including ascorbic acid, ⁇ -tocopherol, ⁇ -carotene, reduced glutathione, uric acid, and bilirubin.
• the sum of endogenous and food-derived antioxidants represents the total antioxidant activity of the extracellular fluid. Cooperation of all the different antioxidants provides greater protection against attack by reactive oxygen or nitrogen radicals, than any single compound alone.
• Cyclooxygenase (COX) assay An in vitro cyclooxygenase-1 and -2 (COX-1, -2) inhibition assay.
• COX is a bifunctional enzyme exhibiting both cyclooxygenase and peroxidase activities.
• the cyclooxygenase activity converts arachidonic acid to a hydroperoxy endoperoxide (Prostaglandin G2; PGG2) and the peroxidase component reduces the endoperoxide (Prostaglandin H2; PGH2) to the corresponding alcohol, the precursor of prostaglandins, thromboxanes, and prostacyclins.
• This COX Inhibitor Screening Assay measures the peroxidase component of cyclooxygenases. The peroxidase activity is assayed colorimetrically by monitoring the appearance of oxidized N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD).
• TMPD oxidized N,N,N′,N′-tetramethyl-p-phenylenediamine
• This inhibitor screening assay includes both COX-1 and COX-2 enzymes in order to screen isozyme-specific inhibitors.
• Tumor necrosis factor alpha (TNF- ⁇ ) assay The prototype ligand of the TNF superfamily, TNF- ⁇ , is a pleiotropic cytokine that plays a central role in inflammation. Increase in its expression is associated with an up regulation in pro-inflammatory activity.
• This bioassay analyzes the effect of compounds on the production of TNF- ⁇ by human epidermal keratinocytes. The endpoint of this assay is a spectrophotometric measurement that reflects the presence of TNF- ⁇ and cellular viability.
• the assay employs the quantitative sandwich enzyme immunoassay technique whereby a monoclonal antibody specific for TNF- ⁇ has been pre-coated onto a microplate.
• TNF- ⁇ TNF- ⁇ bound by the immobilized antibody.
• an enzyme-linked polyclonal antibody specific for TNF- ⁇ is added to the wells.
• a substrate solution is added to the wells and color develops in proportion to the amount of TNF- ⁇ bound in the initial step using a microplate reader for detection at 450 nm. The color development is stopped and the intensity of the color is measured.
• TNF- ⁇ protein was quantified by comparison of optical density units to standard concentrations of purified TNF- ⁇ protein. Values are calculated as % change in the amount of TNF- ⁇ protein secreted between control and treated samples. Negative values reflect the ability of test compounds to reduce the secretion of TNF- ⁇ under conditions known to induce skin irritation (PMA addition) compared to untreated controls.
• Matrix metalloproteinase enzyme activity (MMP3; MMP9) assay An in vitro matrix metalloprotease (MMP) inhibition assay.
• MMPs are extracellular proteases that play a role in many normal and disease states by virtue of their broad substrate specificity.
• MMP3 substrates include collagens, fibronectins, and laminin; while MMP9 substrates include collagen VII, fibronectins and laminin.
• this assay is designed to measure protease activity of MMPs using a thiopeptide as a chromogenic substrate (Ac-PLG-[2-mercapto-4-methyl-pentanoyl]-LG-OC2H5)5,6.
• the MMP cleavage site peptide bond is replaced by a thioester bond in the thiopeptide.
• compositions of the present invention that can include an aromatic skin-active ingredient are described in Tables 5 and 6.
• composition Continue mixing and allow composition to cool to 30° C. Subsequently, add phase C ingredient while mixing. **The aromatic skin-active ingredients identified throughout this specification can be incorporated into this composition. Additionally, any combination of such ingredients (including 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more) can be incorporated into a single composition. In such a case, the concentration ranges can be modified as desired or needed.
• any combination of such ingredients can be incorporated into a single composition.
• the concentration ranges can be modified as desired or needed.
• compositions of the present inventions can be determined by methods known to those of ordinary skill in the art.
• the following are non-limiting procedures that can be used in the context of the present invention. It should be recognized that other testing procedures can be used, including, for example, objective and subjective procedures.
• Skin moisture/hydration can be measured by using impedance measurements with the Nova Dermal Phase Meter.
• the impedance meter measures changes in skin moisture content.
• the outer layer of the skin has distinct electrical properties. When skin is dry it conducts electricity very poorly. As it becomes more hydrated increasing conductivity results. Consequently, changes in skin impedance (related to conductivity) can be used to assess changes in skin hydration.
• the unit can be calibrated according to instrument instructions for each testing day. A notation of temperature and relative humidity can also be made. Subjects can be evaluated as follows: prior to measurement they can equilibrate in a room with defined humidity (e.g., 30-50%) and temperature (e.g., 68-72° C.).
• T5 setting can be used on the impedance meter which averages the impedance values of every five seconds application to the face. Changes can be reported with statistical variance and significance.
• Skin clarity and the reduction in freckles and age spots can be evaluated using a Minolta Chromometer. Changes in skin color can be assessed to determine irritation potential due to product treatment using the a* values of the Minolta Chroma Meter. The a* value measures changes in skin color in the red region. This is used to determine whether a composition is inducing irritation. The measurements can be made on each side of the face and averaged, as left and right facial values. Skin clarity can also be measured using the Minolta Meter. The measurement is a combination of the a*, b, and L values of the Minolta Meter and is related to skin brightness, and correlates well with skin smoothness and hydration. Skin reading is taken as above. In one non-limiting aspect, skin clarity can be described as L/C where C is chroma and is defined as (a 2 +b 2 ) 1/2 .
• Skin dryness, surface fine lines, skin smoothness, and skin tone can be evaluated with clinical grading techniques.
• clinical grading of skin dryness can be determined by a five point standard Kligman Scale: (0) skin is soft and moist; (1) skin appears normal with no visible dryness; (2) skin feels slightly dry to the touch with no visible flaking; (3) skin feels dry, tough, and has a whitish appearance with some scaling; and (4) skin feels very dry, rough, and has a whitish appearance with scaling. Evaluations can be made independently by two clinicians and averaged.
• Clinical grading of skin tone can be performed via a ten point analog numerical scale: (10) even skin of uniform, pinkish brown color. No dark, erythremic, or scaly patches upon examination with a hand held magnifying lens. Microtexture of the skin very uniform upon touch; (7) even skin tone observed without magnification. No scaly areas, but slight discolorations either due to pigmentation or erythema. No discolorations more than 1 cm in diameter; (4) both skin discoloration and uneven texture easily noticeable. Slight scaliness. Skin rough to the touch in some areas; and (1) uneven skin coloration and texture. Numerous areas of scaliness and discoloration, either hypopigmented, erythremic or dark spots. Large areas of uneven color more than 1 cm in diameter. Evaluations were made independently by two clinicians and averaged.
• Clinical grading of skin smoothness can be analyzed via a ten point analog numerical scale: (10) smooth, skin is moist and glistening, no resistance upon dragging finger across surface; (7) somewhat smooth, slight resistance; (4) rough, visibly altered, friction upon rubbing; and (1) rough, flaky, uneven surface. Evaluations were made independently by two clinicians and averaged.
• Skin smoothness and wrinkle reduction can also be assessed visually by using the methods disclosed in Packman et al. (1978). For example, at each subject visit, the depth, shallowness and the total number of superficial facial lines (SFLs) of each subject can be carefully scored and recorded. A numerical score was obtained by multiplying a number factor times a depth/width/length factor. Scores are obtained for the eye area and mouth area (left and right sides) and added together as the total wrinkle score.
• SFLs superficial facial lines
• Skin firmness can be measured using a Hargens ballistometer, a device that evaluates the elasticity and firmness of the skin by dropping a small body onto the skin and recording its first two rebound peaks.
• the ballistometry is a small lightweight probe with a relatively blunt tip (4 square mm-contact area) was used. The probe penetrates slightly into the skin and results in measurements that are dependent upon the properties of the outer layers of the skin, including the stratum corneum and outer epidermis and some of the dermal layers.
• Skin softness/suppleness can be evaluated using the Gas Bearing Electrodynamometer, an instrument that measures the stress/strain properties of the skin.
• the viscoelastic properties of skin correlate with skin moisturization. Measurements can be obtained on the predetermined site on the cheek area by attaching the probe to the skin surface with double-stick tape. A force of approximately 3.5 gm can be applied parallel to the skin surface and the skin displacement is accurately measured. Skin suppleness can then be calculated and is expressed as DSR (Dynamic Spring Rate in gm/mm).
• DSR Dynamic Spring Rate in gm/mm
• the appearance of lines and wrinkles on the skin can be evaluated using replicas, which is the impression of the skin's surface. Silicone rubber like material can be used.
• the replica can be analyzed by image analysis. Changes in the visibility of lines and wrinkles can be objectively quantified via the taking of silicon replicas form the subjects' face and analyzing the replicas image using a computer image analysis system. Replicas can be taken from the eye area and the neck area, and photographed with a digital camera using a low angle incidence lighting. The digital images can be analyzed with an image processing program and the are of the replicas covered by wrinkles or fine lines was determined.
• the surface contour of the skin can be measured by using the profilometer/Stylus method. This includes either shining a light or dragging a stylus across the replica surface.
• the vertical displacement of the stylus can be fed into a computer via a distance transducer, and after scanning a fixed length of replica a cross-sectional analysis of skin profile can be generated as a two-dimensional curve. This scan can be repeated any number of times along a fix axis to generate a simulated 3-D picture of the skin.
• Ten random sections of the replicas using the stylus technique can be obtained and combined to generate average values.
• the values of interest include Ra which is the arithmetic mean of all roughness (height) values computed by integrating the profile height relative to the mean profile height.
• the efficacy of the compositions of the present invention can be evaluated by using a skin analog, such as, for example, MELANODERMTM.
• a skin analog such as, for example, MELANODERMTM.
• Melanocytes one of the cells in the skin analog, stain positively when exposed to L-dihydroxyphenyl alanine (L-DOPA), a precursor of melanin.
• L-DOPA L-dihydroxyphenyl alanine
• the skin analog, MELANODERMTM can be treated with a variety of bases containing the compositions and whitening agents of the present invention or with the base alone as a control. Alternatively, an untreated sample of the skin analog can be used as a control.
• Oxygen Radical Absorption (or Absorbance) Capacity (ORAC) of the aromatic skin-active ingredients and compositions can also be assayed by measuring the antioxidant activity of such ingredients or compositions.
• This assay can quantify the degree and length of time it takes to inhibit the action of an oxidizing agent such as oxygen radicals that are known to cause damage cells (e.g., skin cells).
• the ORAC value of the aromatic skin-active ingredients and compositions can be determined by methods known to those of ordinary skill in the art (see U.S. Publication Nos. 2004/0109905 and 2005/0163880; Cao et al. (1993)), all of which are incorporated by reference).
• the assay described in Cao et al. (1993) measures the ability of antioxidant compounds in test materials to inhibit the decline of B-phycoerythrm (B-PE) fluorescence that is induced by a peroxyl radical generator, AAPH.
• B-PE B-phycoerythrm
• aromatic skin-active ingredients, compositions, or methods disclosed and claimed in this specification can be made and executed without undue experimentation in light of the present disclosure. While the aromatic skin-active ingredients, compositions, or methods of this invention have been described in terms of particular embodiments, it will be apparent to those of skill in the art that variations may be applied to the aromatic skin-active ingredients, compositions, or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Emergency Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Dermatology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=40932318

Family Applications (3)

Family Applications After (2)

Country Status (11)

Cited By (12)

Families Citing this family (5)

Citations (6)

Family Cites Families (13)

• 2008
  • 2008-04-18 KR KR1020080036286A patent/KR101199672B1/ko active IP Right Grant
  • 2008-04-18 US US12/105,957 patent/US20090197939A1/en not_active Abandoned
  • 2008-05-20 CN CN200810100531.2A patent/CN101496799B/zh not_active Expired - Fee Related
  • 2008-05-20 CN CN201410115268.XA patent/CN103919767B/zh not_active Expired - Fee Related
• 2009
  • 2009-01-29 CA CA2713770A patent/CA2713770C/en active Active
  • 2009-01-29 MX MX2010008293A patent/MX2010008293A/es active IP Right Grant
  • 2009-01-29 WO PCT/US2009/032430 patent/WO2009099890A2/en active Application Filing
  • 2009-01-29 EA EA201001195A patent/EA020293B1/ru not_active IP Right Cessation
  • 2009-01-29 EP EP09707381.1A patent/EP2257284B1/en not_active Not-in-force
  • 2009-01-29 MX MX2013001686A patent/MX360399B/es unknown
  • 2009-01-29 BR BRPI0907086-9A patent/BRPI0907086B1/pt not_active IP Right Cessation
  • 2009-01-29 ES ES09707381.1T patent/ES2540743T3/es active Active
• 2010
  • 2010-06-09 US US12/796,820 patent/US8399521B2/en active Active
• 2015
  • 2015-01-13 HK HK15100340.0A patent/HK1199834A1/zh not_active IP Right Cessation
• 2019
  • 2019-06-25 US US16/451,999 patent/US20190314295A1/en active Pending

Patent Citations (6)

Non-Patent Citations (8)

Also Published As

Similar Documents

Legal Events